Research published online by the Journal of the National Comprehensive Cancer Network (JNCCN) finds that for many commonly-used treatment regimens targeting metastatic gastrointestinal (GI) cancers, such as FOLFOX, FOLFIRI, or FOLFIRINOX, it is possible to administer 5-FU solely through continuous infusion, minus the bolus (quick-delivery via intravenous push) component, without negatively affecting patient outcomes.
This article was originally published on MedicalXpress.com